A Phase 3 interventional study of GABITRIL (tiagabine hydrochloride; CEP-6671) in General Anxiety Disorder, sponsored by Cephalon. Completed at 28 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by Cephalon (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
517 studies on the registry are indexed under Generalized Anxiety Disorder; 124 are open to participants now.
Browse Generalized Anxiety Disorder studies →Cephalon is the lead sponsor of 75 studies on the registry; none are open to participants now.
First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd..
Counted across the registry records on this site, refreshed daily.
Not available at time of registration
The record gives a start of Aug 2003 and a primary completion of Feb 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tiagabine
Generalized Anxiety Disorder →